Background. Azithromycin has demonstrated in vitro and in vivo activity against Plasmodium falciparum, but small treatment studies have given mixed results.
The spread of chloroquine-resistant Plasmodium falciparum has had a major impact on both the health of residents in areas where the parasite is endemic and the choice of treatment for malaria. Although public-health authorities have moved to other drugs as first-line therapy, these options have been restricted by a variety of considerations. Pyrimethamine-sulfadoxine is inexpen-sive and readily available, but resistance to its use is developing in many regions. Artemesinin derivatives are extremely potent, but, to prevent relapse, they must be used in combination with other therapies; and there are questions regarding their safety. Quinine is also inexpensive and widely available, but its side effects are not insignificant, and, in many countries, resistance has precluded its use as monotherapy; also, 7 days of treatment are required. Combination therapies are being broadly endorsed, both to delay the emergence of resistance and to restore the utility of older compounds [1] ; examples include quinine-tetracycline, atovoaquine-proguanil, chlorproguanil-dapsone, and artemesinins combined with various other antimalarial drugs.
Azithromycin has demonstrated in vitro and in vivo activity against P. falciparum [2] . As monotherapy, it has been found to have modest prophylactic activity against falciparum-related disease [3, 4] and, in combination therapy with artensuate, has demonstrated mixed results in small studies [5, 6] . Its activity as monotherapy and in combination therapy with 4-aminoquinolines has not been investigated. A clinical trial was therefore undertaken to explore its use in the treatment of acute uncomplicated malaria due to P. falciparum.
PARTICIPANTS, MATERIALS, AND METHODS

Selection of participants.
This study was conducted in India-in the states of Gujarat, Delhi, Madhya Pradesh, Orissa, and Assam-during July 1998-October 2001; in these states, there is a stable transmission of malaria throughout the year, with an increased incidence during the rainy season. Participants were recruited from the outpatient clinics of 7 centers experienced in the treatment of malaria. The study included 2 independent strata, 1 for participants with falciparum malaria and 1 for participants with vivax malaria. The results from the vivax stratum are the subject of a separate report.
After providing informed consent, participants were assigned, on the basis of a rapid diagnostic test and a confirmatory peripheral-blood smear for malaria, to either the vivax stratum or the falciparum stratum, if they were 18-65 years of age, had !100,000 parasites/mL on the baseline blood smear, and, during the preceding 48 h, had had a fever 138ЊC; in addition, women participants were required to have tested negative, by a urine test, for human chorionic gonadotropin-b and to be willing to use adequate contraception both during and for 3 months after the study. Participants were excluded from the study if they had clinical evidence of impaired consciousness, jaundice, and/or respiratory distress; had a history of hematuria; had a serum glucose level less than the lower limit of normal; were pregnant or lactating; had been treated with any antimalarial drug during the preceding 15 days; had received a transfusion of red blood cells during the preceding 28 days; and/or had laboratory or clinical evidence of significant abnormality of cardiovascular, liver, or renal function.
Procedures. As a quantitative assessment of parasitemia, a thin blood smear counterstained with Giemsa was examined every 8 h; all participants remained hospitalized until 2 consecutive blood smears were negative, but, for every participant, blood smears were tested once daily through day 7. Any participant who, in the opinion of the investigator, had not sufficiently improved received additional antimalarial therapy. Laboratory examinations included a test for baseline level of glucose-6 phosphate dehydrogenase and, both at baseline and on day 3, a complete blood count and tests for levels of bilirubin and aspartate aminotransferase. Before they were enrolled in the study, women with the potential to bear children were required to have a urinetest result that was negative for human chorionic gonadotropinb. Participants returned to the clinic on days 7, 14, and 28, for medical history, physical examination, and follow-up blood smears.
Personnel at the sites received training, at a central site, in the reading of blood smears, including the use of quality-control slide sets. Investigators attended specifically designed courses in good clinical practice, and, to insure coordination between sites, logistics training was provided by the sponsor (Pfizer).
At each site, the informed-consent form was translated into the local language. The protocol and all its amendments, as well as the informed-consent form, were reviewed and approved by the institutional review board at each participating center.
Participants were randomly assigned to 1 of the following 2 groups: (1) a therapy regimen of 1 g (2 ϫ 500-mg tablet) of azithromycin, with a matching chloroquine placebo, for 3 days, or (2) a therapy regimen of both 600 mg base (4 ϫ 150-mg base tablet) of chloroquine for 2 days and 300 mg base (2 ϫ 150-mg base tablet) of chloroquine on day 3, with a matching azithromycin placebo for all 3 days. Although the participants selected for this stage of the study were appropriate for outpatient therapy, they were admitted to and monitored in the hospital.
Laboratory methods. A rapid diagnostic test for falciparum malaria was performed on each participant, by use of either ParaSight F (Becton Dickinson) or ICT (ICT Diagnostics). Thick and thin blood smears were prepared by use of Giemsa stain. Parasite concentration was determined on the basis of the number of asexual parasites-including ring forms, trophozoites, and schizonts-per 200 white blood cells (WBCs) in the thick blood smear. Parasitemia was calculated by use of the following formula: (no. of parasites/200 WBCs) ϫ (no. of WBCs/mL) p no. of parasites/mL, with the WBC count obtained from the coincident hematologic evaluation at baseline. A blood smear was considered to have a negative result if no parasites were seen in 50 high-power fields.
Sample size. A sample size of 250 participants was selected to provide 80% power at an a level of 0.05, so that the lower limit of the efficacy-rate difference between azithromycin and chloroquine would be Ϫ15%, under the assumption that each of these monotherapy regimens would have a response rate of 80%. An interim analysis was planned after 32 participants with falciparum malaria had completed treatment. This sample size at the interim analysis would provide ∼80% power to demonstrate, with a 1-sided a level of 0.001, that azithromycin was not 50% less effective than chloroquine, under the assumption that each of the monotherapy regimens would have a response rate of 80%.
Statistical analyses. Analyses for both stages of the study were performed on the basis of both the group of intent-totreat participants and the group of evaluable participants; the results presented here are for the evaluable group and are similar to those for the intent-to-treat group. When data were missing, either data from the previous visit were substituted (in the case of the analysis of the intent-to-visit group) or data available within the visit window were substituted (in the case of the analysis of the evaluable group). The evaluable partici- pants (1) had baseline falciparum parasitemia of !100,000 parasites/mL, (2) had completed 3 days of therapy, and (3) had an assessment of fever, considered to be the highest temperature recorded that day, all occurring within the appropriate time frame. Treatment failure was defined in terms of the following 3 categories: RI (recrudescence after clearance of parasitemia), RII (reduction in parasitemia to !25% of baseline levels, without clearance), and RIII (failure to reduce parasitemia to !25% of baseline levels). Participants who received antimalarial medication because of treatment failure were, from that point forward, considered as representing cases of treatment failure. The primary statistical test for assessing the equivalence of azithromycin versus chloroquine was a 2-sided 95.1% confidence interval (CI) for the difference, in clinical response, at day 7. CIs for the difference in clinical response at days 3, 7, 14, and 28 were calculated by use of the exact method of Mehta and Patel rather than by normal approximation to the binomial. The success rate during the combination-therapy stage was estimated by construction of 95% Blyth-Still-Casella CIs, by use of exact methods based on the binomial distribution. All exact analyses were done by use of StatXact 4 for Windows (CYTEL Software).
To account for the interim analysis, an adjustment of 0.001 was made to the overall a level. 95.1% CIs were constructed for the response-rate differences between the 2 monotherapies, by use of the exact method of Mehta and Patel rather than by normal approximation to binomial (StatXact 4 for Windows; CYTEL Software). After the interim analysis, the sample size was reduced to 65 participants, so that the lower limit of the 95% CI for the success rate would be close to 95%, under the assumption that a true success rate would be almost 100%.
Study-design modification after the interim analysis. When the interim analysis revealed inadequate therapeutic response, the protocol was amended so that all future participants with falciparum malaria would be treated, in an open-label fashion, with combination therapy in which the doses of azithromycin and chloroquine were the same as those used in monotherapy (Figure 1) .
RESULTS
Monotherapy.
A total of 32 participants, half from Vadodara and half from Guwahati, were enrolled in the double-blind portion of the study. The baseline demographic characteristics of the participants randomized to each of the 2 monotherapy regimens were similar (table 1). Figure 2 shows parasite counts during the course of treatment. Table 2 shows that, by day 7, a total of 14 (88%) of the 16 evaluable participants receiving chloroquine were considered to be clinically cured, compared with 10 (63%) of the 16 evaluable participants receiving azithromycin (difference, Ϫ25% [95.1% CI, Ϫ58 to 13]); and, as shown in table 3, analysis of the resolution of parasitemia revealed similar results. The median time at resolution of parasitemia was 57 h and 96 h for monotherapy with chloroquine and azithromycin, respectively. Although these findings did not fulfill the predefined rule for discontinuing the trial at the time of the interim analysis, table 2 shows that the day 28 results revealed cure rates of 33% and 27% for azithromycin and chloroquine, respectively, results that were significantly below the clinical-cure rates that had been presumed at the initiation of the trial. As a consequence, monotherapy for participants infected with falciparum malaria was discontinued, and the protocol was amended to allow them to be treated with the combination of azithromycin and chloroquine.
Combination therapy. Of the 64 participants enrolled in the open-label, combination-therapy phase of the study, 41 (64%) were from Guwahati, with the remainder being from Jabalpur, Behrampur, and Vadodara. The demographic characteristics of these participants were similar to those of the initial cohort, with the exception of baseline parasitemia (table 1). Figure 2 shows the parasite counts during the course of treatment. In 56 (88%) of the 64 participants, resolution of fever and parasitemia occurred by day 3, and, in 61 (97%) of 63 participants, it occurred by day 7. Through day 28, no participant had a recrudescence of infection. The median time to resolution of parasitemia was 36 h.
One participant was considered to be a category RIII treatment failure, having presented with a baseline count of 94,080 Figure 1 . Status of participants before and after interim analysis parasites/mL and, within 8 h, having a count of 172,800 parasites/mL. Although no clinical deterioration was observed, this participant was given quinine, in accordance with the protocol targeted to participants with counts of !100,000 parasites/mL. Another participant presented with a baseline count of 3456 parasites/mL, and, within 48 h, resolution of his parasitemia and fever had occurred; because he received a dose of quinine before a second blood smear could be found to be negative, he was considered, from that point forward, to be a category RII treatment failure.
More than half of the participants receiving either azithromycin or chloroquine in the double-blind, monotherapy phase of the trial reported treatment-related adverse events. During the open-label, combination-therapy phase of the study, 20% reported a treatment-related adverse event, and all of these events except one (pruritis) were considered to be mild (table 4) .
DISCUSSION
The results of this clinical trial are notable for 3 reasons. First, they demonstrate that azithromycin, at a dose of 1 g/day for 3 days, would not be useful as monotherapy for falciparum malaria. Second, chloroquine, at its standard dose, achieved, at the 4 sites in India, a lower cure rate at day 28 than would be expected for treatment of fully sensitive organisms. Third, the results demonstrate that combination therapy with both azithromycin and chloroquine, at the same doses that had been used in monotherapy, could achieve clinical success at acceptable rates.
An earlier study has reported that category RI chloroquine resistance in India is increasing at a rate of 18% [7] . Overall, category RI resistance, measured through day 28, approached 70% and was similar at all 4 of the sites in India that were considered in the present study. This degree of chloroquine resistance is consistent with that in the Asian subcontinent in general.
Resolution of parasitemia during the first 7 days was slower for monotherapy with azithromycin (figure 2). Clindamycin, another inhibitor of protein synthesis, has been found to produce a similarly delayed resolution of parasitemia; the antimalarial effect of clindamycin has not been firmly established, but it has been shown to act on plasmodial 70S ribosomespecific protein synthesis [8] . Although azithromycin is known to target the bacterial ribosome and is presumed to target the plasmodial ribosome, the latter activity has not been established. Explanations for the delay in resolution of parasitemia could include lack of penetration into the parasite and/or inadequate accumulation of these compounds at the site of action. Alternatively, the organism may have previously synthesized enough protein to allow for at least 1 additional cycle of replication before parasiticidal effects could be demonstrated. Interestingly, interference with the apicomplexan plastid-perhaps, in this case, through the inhibition of plastid-specific ribosomal protein-has resulted in the phenomenon of delayed cell death [9] .
A precedent exists for expecting enhanced activity from combination therapy with a protein synthesis inhibitor and a 4-aminoquinoline. Three small clinical trials have reported improvements in clinical efficacy when clindamycin is used in combination with either chloroquine or quinine [10] [11] [12] . The clinical efficacy of the combination of azithromycin and chloroquine is supported by in vitro data demonstrating synergy between these 2 drugs. This in vitro synergy appears to be most pronounced in organisms that are isolated from regions where higher levels of clinical chloroquine resistance have been identified [13] ; if this is the case, then these findings parallel those observed for verapamil [14] , which is suspected to interfere with the modified pfcrt-gene product associated with chloroquine resistance [15, 16] ; however, it has not been determined whether azithromycin similarly interferes with the pfcrt-gene product. It is also possible that azithromycin inhibits the function of other compensatory mutations in the resistant parasite, thereby impairing the fitness of the resistant organism. Alternatively, because azithromycin is also a weak base, it may, like chloroquine, raise the pH of the digestive vacuole, thereby preventing the organism from managing accumulated hematin. In light of the small sample size used in the monotherapy phase of the present study, it is difficult to compare the adverseevent rates of the monotherapy regimens versus those of the open-label, combination-therapy regimen. The rates and types of adverse events reported for the combination therapy are, however, consistent with the known side effects of these drugs, were essentially mild, and did not require discontinuation of therapy.
There are a number of limitations in the present study. The baseline parasite counts observed in the combination-therapy regimen were lower than those in the monotherapy regimens, which may have occurred because a greater proportion of the enrollment in the combination-therapy regimen occurred during the dry season. However, in an analysis of 14 participants treated with the combination therapy who had some of the highest baseline parasite counts, the initial resolution of parasitemia was similar to that observed in the monotherapy regimen with chloroquine (data not shown).
Because different strains of P. falciparum may carry different chloroquine-resistance mechanisms, the findings of the present study are most relevant to the geographic sites at which it was conducted. Whether combination therapy with azithromycin and chloroquine will result in similar outcomes in other geographic areas-specifically, in regions where category RII and RIII resistance predominate-remains to be determined. The recent experience in Thailand, where azithromycin was used in combination with quinine, another 4-aminoquinoline that has demonstrated similar in vitro synergy with azithromycin, is encouraging in this regard [17] . It should also be noted that only a single dose (1 g/day for 3 days) of azithromycin was used in the present study and that lower doses may have similar effects.
If the findings of the present study are reproducible, then the combination therapy of azithromycin and chloroquine may be a promising alternative for the treatment of malaria in regions with chloroquine resistance. Azithromycin and chloroquine are both considered to be safe for children, and the results seen when azithromycin has been used to treat pregnant women have been encouraging [18] . The once-daily, 3-day therapy regimen would be simple to administer and builds on the extensive experience with chloroquine therapy. In addition, azithromycin and chloroquine are widely available in regions where malaria is endemic-and their currently defined prices in these countries make combination therapy with them a potentially cost-effective alternative. Although the discovery of new chemical entities with activity against plasmodia remains a priority, this combination therapy may prolong the useful life of chloroquine until such new entities are available for clinical use.
In summary, monotherapy with azithromycin should not be used to treat falciparum malaria; however, in India, combination therapy with azithromycin and chloroquine has been demonstrated to have clinical efficacy in a region of category RI chloroquine resistance, at a rate consistent with historical rates of efficacy for chloroquine alone. Additional clinical studies to confirm these findings will be an important step toward defining this combination therapy as an alternative regimen for treatment of falciparum malaria in areas where there is chloroquine resistance.
